BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 179-191

  Pickup, Michael W ^a   Hover, Laura D ^a   Polikowsky, Eleanor R ^a   Chytil, Anna ^a   Gorska, Agnieszka E ^a   Novitskiy, Sergey V ^a   Moses, Harold L ^a   Owens, Philip ^a  

^a Department of Cancer Biology ^*  (United States)

Author keywords

Bone morphogenetic proteins; Breast cancer; Carcinoma associated fibroblast; Chemokines; Fibroblasts; Inflammation; Metastasis; Tumor microenvironment

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALVASCULIN; CASPASE 3; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; PHALLOIDIN; RANTES; SMAD6 PROTEIN; SMAD7 PROTEIN; VIMENTIN; BMPR2 PROTEIN, HUMAN; BMPR2 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; LUNG METASTASIS; MOUSE; NONHUMAN; ANIMAL; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; INFLAMMATION; METABOLISM; METASTASIS; PATHOLOGY;

MUS;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BREAST NEOPLASMS; FEMALE; FIBROBLASTS; GENE DELETION; HUMANS; INFLAMMATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84920383333     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.004     Document Type: Article

References (47)

1. Achyut B.R., Bader D.A., Robles A.I., Wangsa D., Harris C.C., Ried T., Yang L. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet. 2013, 9:e1003251.
2. Alarmo E.L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr. Relat. Cancer 2010, 17:R123-R139.
3. Austin E.D., Menon S., Hemnes A.R., Robinson L.R., Talati M., Fox K.L., Cogan J.D., Hamid R., Hedges L.K., Robbins I., Lane K., Newman J.H., Loyd J.E., West J. Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. Pulm. Circ. 2011, 1:389-398.
4. Barlow J., Yandell D., Weaver D., Casey T., Plaut K. Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Res. Treat. 2003, 79:149-159.
5. Beppu H., Lei H., Bloch K.D., Li E. Generation of a floxed allele of the mouse BMP type II receptor gene. Genesis 2005, 41:133-137.
6. Beppu H., Mwizerwa O.N., Beppu Y., Dattwyler M.P., Lauwers G.Y., Bloch K.D., Goldstein A.M. Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation. Oncogene 2008, 27:1063-1070.
7. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
8. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
9. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
10. Boomershine C.S., Chamberlain A., Kendall P., Afshar-Sharif A.R., Huang H., Washington M.K., Lawson W.E., Thomas J.W., Blackwell T.S., Bhowmick N.A. Autoimmune pancreatitis results from loss of TGFbeta signalling in S100A4-positive dendritic cells. Gut 2009, 58:1267-1274.
11. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res. 2008, 6:1521-1533.
12. Ehata S., Yokoyama Y., Takahashi K., Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?. Pathol. Int. 2013, 63:287-296.
13. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., Hallett M., Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
14. Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W., Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G., Pistorius S., Burger B., Propping P. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum. Genet. 2002, 111:108-111.
15. Gamer L.W., Tsuji K., Cox K., Capelo L.P., Lowery J., Beppu H., Rosen V. BMPR-II is dispensable for formation of the limb skeleton. Genesis 2011, 49:719-724.
16. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., Shen R., Brogi E., Brivanlou A.H., Giancotti F.G. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
17. Gorges T.M., Tinhofer I., Drosch M., Rose L., Zollner T.M., Krahn T., von Ahsen O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12:178.
18. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 1992, 12:954-961.
19. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
20. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 2001, 28:184-187.
21. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
22. Ketolainen J.M., Alarmo E.L., Tuominen V.J., Kallioniemi A. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res. Treat. 2010, 124:377-386.
23. Kong P., Christia P., Saxena A., Su Y., Frangogiannis N.G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am. J. Physiol. Heart Circulatory Physiol. 2013, 305:H1363-H1372.
24. Kwon S.J., Lee G.T., Lee J.H., Iwakura Y., Kim W.J., Kim I.Y. Mechanism of pro-tumorigenic effect of BMP-6: neovascularization involving tumor-associated macrophages and IL-1a. The Prostate 2014, 74:121-133.
25. Lee J.H., Lee G.T., Woo S.H., Ha Y.S., Kwon S.J., Kim W.J., Kim I.Y. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 2013, 73:3604-3614.
26. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J.Biochem. 2010, 147:35-51.
27. Miyazono K., Maeda S., Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005, 16:251-263.
28. Morales M., Planet E., Arnal-Estape A., Pavlovic M., Tarragona M., Gomis R.R. Tumor-stroma interactions a trademark for metastasis. Breast 2011, 20(Suppl.3):S50-S55.
29. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
30. Muzumdar M.D., Tasic B., Miyamichi K., Li L., Luo L. A global double-fluorescent Cre reporter mouse. Genesis 2007, 45:593-605.
31. Novitskiy S.V., Pickup M.W., Gorska A.E., Owens P., Chytil A., Aakre M., Wu H., Shyr Y., Moses H.L. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov. 2011, 1:430-441.
32. Osterreicher C.H., Penz-Osterreicher M., Grivennikov S.I., Guma M., Koltsova E.K., Datz C., Sasik R., Hardiman G., Karin M., Brenner D.A. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl. Acad. Sci. U S A 2011, 108:308-313.
33. Owens P., Engelking E., Han G., Haeger S.M., Wang X.J. Epidermal Smad4 deletion results in aberrant wound healing. Am. J. Pathol. 2010, 176:122-133.
34. Owens P., Pickup M.W., Novitskiy S.V., Chytil A., Gorska A.E., Aakre M.E., West J., Moses H.L. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc. Natl. Acad. Sci. U S A 2012, 109:2814-2819.
35. Owens P., Polikowsky H., Pickup M.W., Gorska A.E., Jovanovic B., Shaw A.K., Novitskiy S.V., Hong C.C., Moses H.L. Bone morphogenetic proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. PloS One 2013, 8:e67533.
36. Pickup M., Novitskiy S., Moses H.L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 2013, 13:788-799.
37. Pickup M.W., Laklai H., Acerbi I., Owens P., Gorska A.E., Chytil A., Aakre M., Weaver V.M., Moses H.L. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas. Cancer Res. 2013, 73:5336-5346.
38. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
39. Song Y., Coleman L., Shi J., Beppu H., Sato K., Walsh K., Loscalzo J., Zhang Y.Y. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am. J. Physiol. Heart circulatory Physiol. 2008, 295:H677-H690.
40. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
41. Talati M., West J., Zaynagetdinov R., Hong C.C., Han W., Blackwell T., Robinson L., Blackwell T.S., Lane K. BMP pathway regulation of and by macrophages. PloS One 2014, 9:e94119.
42. Tuder R.M., Archer S.L., Dorfmuller P., Erzurum S.C., Guignabert C., Michelakis E., Rabinovitch M., Schermuly R., Stenmark K.R., Morrell N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J.Am. Coll. Cardiol. 2013, 62:D4-D12.
43. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
44. Workman P., Aboagye E.O., Balkwill F., Balmain A., Bruder G., Chaplin D.J., Double J.A., Everitt J., Farningham D.A., Glennie M.J., Kelland L.R., Robinson V., Stratford I.J., Tozer G.M., Watson S., Wedge S.R., Eccles S.A. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 2010, 102:1555-1577. Committee of the National Cancer Research Institute.
45. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
46. Yang S., Pham L.K., Liao C.P., Frenkel B., Reddi A.H., Roy-Burman P. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res. 2008, 68:198-205.
47. Yu P.B., Beppu H., Kawai N., Li E., Bloch K.D. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J.Biol. Chem. 2005, 280:24443-24450.